Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06071845 · ClinicalTrials.gov registry record · NA
Assessment of a Minimally Invasive Collection Device for Molecular Analysis of Esophageal Samples
A NA study of Esophageal Adenocarcinoma and Barrett Esophagus, sponsored by Mayo Clinic.
- Recruiting
- Registry status
- NA
- Development phase
- 400
- Enrollment target
- 5
- Study locations
NCT06071845 is a NA study of Esophageal Adenocarcinoma and Barrett Esophagus that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 400 participants, above the 299-participant average among 43 other Esophageal Adenocarcinoma trials with a reported enrollment target (34% higher). The trial reports 5 study locations across 5 states.
The verdict
NCT06071845, a NA study of Esophageal Adenocarcinoma and Barrett Esophagus, is actively recruiting participants, sponsored by Mayo Clinic.
- RECRUITING
- Registry status
- NA
- Development phase
- 400 participants
- Enrollment target
- 5
- Study locations
Study Summary
This clinical trial evaluates the use of cytosponge, a minimally invasive collection device, for the detection of Barrett's esophagus (BE) in patients undergoing endoscopy. Non-endoscopic swallowable encapsulate sponge cell collection devices combined with markers for BE/esophageal adenocarcinoma (EAC) detection are a guideline-endorsed alternative to endoscopy for BE screening. The Oncoguard registered trademark Esophagus test (OGE) test uses esophageal cytology specimens collected with a minimally invasive, non-endoscopic, encapsulated sponge sampling device to identify BE/EAC biomarkers that indicate whether a patient should undergo diagnostic endoscopy. The OGE test is a simple and cost effective screening method that may lower barriers to widespread adoption of BE screening in at risk patients, resulting in increased and earlier detection of BE/EAC.
Conditions Studied
Interventions
- DEVICE Cytosponge Procedure
- DIAGNOSTIC_TEST Endoscopic Assessment
Study Locations (5)
Arizona
- Mayo Clinic - Scottsdale
Florida
- Mayo Clinic in Florida - Jacksonville
Illinois
- Northwestern University - Chicago
Minnesota
- Mayo Clinic in Rochester - Rochester
New York
- Long Island Jewish Medical Center | Northwell Health - New Hyde Park
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 400 participants |
| Start Date | 2023-10-16 |
| Est. Completion | 2026-06-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06071845
The ClinicalTrials.gov registry entry for NCT06071845 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 400 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 299-participant average among 43 other Esophageal Adenocarcinoma trials with a reported enrollment target (34% higher). The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Esophageal Adenocarcinoma appearing as the primary indexed condition, and to 2 interventions - of which Cytosponge Procedure is the first listed.
NCT06071845 reports 5 study locations spanning 5 distinct geographic areas - top geographies include Arizona, Florida, Illinois.
Frequently Asked Questions
What is clinical trial NCT06071845 about?
NCT06071845 is a clinical study titled "Assessment of a Minimally Invasive Collection Device for Molecular Analysis of Esophageal Samples". This clinical trial evaluates the use of cytosponge, a minimally invasive collection device, for the detection of Barrett's esophagus (BE) in patients undergoing endoscopy. Non-endoscopic swallowable encapsulate sponge cell collection devices combined with markers for BE/esophageal adenocarcinoma (E...
What is the current status of trial NCT06071845?
This trial is currently recruiting. It is a NA study. The enrollment target is 400 participants. The study started on 2023-10-16. Estimated completion is 2026-06-01.
What conditions does trial NCT06071845 study?
This clinical trial studies the following conditions: Esophageal Adenocarcinoma, Barrett Esophagus, Barretts Esophagus With Dysplasia, Barrett's Esophagus Without Dysplasia.
What interventions are being tested in trial NCT06071845?
The interventions under investigation include: Cytosponge Procedure (DEVICE), Endoscopic Assessment (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT06071845?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06071845 being conducted?
This trial has 5 study locations across Arizona, Florida, Illinois, Minnesota, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Esophageal Adenocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Minimally Invasive Molecular Approaches for the Diagnosis of Barrett's Esophagus and Esophageal Adenocarcinoma
RECRUITING · NA
-
Seattle Biopsy Protocol Versus Wide-Area Transepithelial Sampling in Patients With Barrett's Esophagus Undergoing Surveillance
RECRUITING · NA
-
Surveillance vs. Endoscopic Therapy for Barrett's Esophagus With Low-grade Dysplasia
RECRUITING · NA
-
Multi-Site Detection of Barrett's Esophagus in Patients Without Chronic GERD Symptoms
RECRUITING · NA
-
Trial to Assess the Effects of an Antimicrobial Mouthwash on the Esophageal Microbiome
COMPLETED · NA
-
Esophageal Cytology With FISH in Detecting Esophageal Cancer
COMPLETED · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.